Recent Advances in the Pharmacoepidemiology of Antirheumatic Medication
A special issue of Pharmacoepidemiology (ISSN 2813-0618).
Deadline for manuscript submissions: 31 December 2024 | Viewed by 340
Special Issue Editors
Interests: rheumatoid arthritis; psoriatic arthritis; systemic lupus erythematosus; Sjogren's syndrome; autoimmune diseases: rheumatic ocular manifestations
Interests: rheumatoid arthritis; psoriatic arthritis; systemic lupus erythematosus
2. Centre for Rheumatology, Department of Medicine, University College London, London, UK
3. Department of Haematology, Cancer Institute, University College London, London, UK
Interests: rheumatoid arthritis; psoriatic arthritis; systemic lupus erythematosus
Special Issue Information
Dear Colleagues,
In our times, understanding the mechanisms, effects, and safety of antirheumatic drugs has become more crucial than ever. These drugs are essential for treating diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and spondyloarthritis (SpA), systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS), systemic sclerosis (SSc), and various autoimmune diseases, including large-vessel and ANCA-associated vasculitis.
The integration of real-world evidence with clinical trial data has significantly enhanced our understanding of the effects of medications across varied patient populations. These advancements are crucial for refining therapeutic strategies and shaping clinical guidelines for rheumatic disease management.
Therefore, it is increasingly important to thoroughly investigate the efficacy, retention rate, and safety of biotechnological drugs such as anti-TNFα, anti-IL-6, anti-IL-23, anti-IL-12/23, anti-IL-17, T cell co-stimulation modulator, anti-I interferon receptor, anti-CD20, and anti-BAFF, as well as JAK inhibitors. It is also important not to overlook the study and re-evaluation of fundamental drugs for autoimmune diseases, such as conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), which continue to play a key role in the management of these patients. Moreover, the role, effects, safety, and long-term perspectives of using corticosteroids and NSAIDs should not be ignored.
This Special Issue aims to keep up to date on current or shifting trends in advances in the pharmacoepidemiology of antirheumatic medications. It will accept original research articles, systematic and narrative review articles, commentaries, letters, or other materials facilitating an understanding of this fundamental topic.
Dr. Roberta Foti
Dr. Beatrice Maranini
Dr. Veronica Venturelli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacoepidemiology is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antirheumatic medication
- rheumatoid arthritis (RA)
- psoriatic arthritis (PsA)
- systemic lupus erythematosus (SLE)
- csDMARDs
- bDMARDs
- JAK inhibitors
- anti-TNFα
- retention rate
- safety
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
